CN107428822B - 抗甲状腺素运载蛋白抗体 - Google Patents

抗甲状腺素运载蛋白抗体 Download PDF

Info

Publication number
CN107428822B
CN107428822B CN201680015800.8A CN201680015800A CN107428822B CN 107428822 B CN107428822 B CN 107428822B CN 201680015800 A CN201680015800 A CN 201680015800A CN 107428822 B CN107428822 B CN 107428822B
Authority
CN
China
Prior art keywords
antibody
ser
val
ttr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680015800.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107428822A (zh
Inventor
塔洛陈·S.·尼扎
A·恰克拉布阿缇
J·N·海加凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neoto Neuroscience Ltd
University Health Network
Novo Nordisk AS
Original Assignee
University Health Network
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, Prothena Biosciences Ltd filed Critical University Health Network
Publication of CN107428822A publication Critical patent/CN107428822A/zh
Application granted granted Critical
Publication of CN107428822B publication Critical patent/CN107428822B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680015800.8A 2015-01-28 2016-01-28 抗甲状腺素运载蛋白抗体 Active CN107428822B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562109001P 2015-01-28 2015-01-28
US62/109,001 2015-01-28
US201562266557P 2015-12-11 2015-12-11
US62/266,557 2015-12-11
PCT/IB2016/050414 WO2016120809A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (2)

Publication Number Publication Date
CN107428822A CN107428822A (zh) 2017-12-01
CN107428822B true CN107428822B (zh) 2021-11-23

Family

ID=55361912

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680015800.8A Active CN107428822B (zh) 2015-01-28 2016-01-28 抗甲状腺素运载蛋白抗体

Country Status (19)

Country Link
US (1) US20160257736A1 (cg-RX-API-DMAC7.html)
EP (1) EP3250594B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875280B2 (cg-RX-API-DMAC7.html)
KR (1) KR102619359B1 (cg-RX-API-DMAC7.html)
CN (1) CN107428822B (cg-RX-API-DMAC7.html)
AU (1) AU2016210887B2 (cg-RX-API-DMAC7.html)
CA (1) CA2974911A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017008469A2 (cg-RX-API-DMAC7.html)
CU (1) CU24532B1 (cg-RX-API-DMAC7.html)
EA (1) EA036048B1 (cg-RX-API-DMAC7.html)
ES (1) ES2905311T3 (cg-RX-API-DMAC7.html)
MX (1) MX391789B (cg-RX-API-DMAC7.html)
MY (1) MY193674A (cg-RX-API-DMAC7.html)
PE (1) PE20180200A1 (cg-RX-API-DMAC7.html)
SA (1) SA517381991B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201706125QA (cg-RX-API-DMAC7.html)
TW (2) TWI718121B (cg-RX-API-DMAC7.html)
WO (1) WO2016120809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201705662B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
EP3691626A4 (en) * 2017-10-06 2021-06-30 Prothena Biosciences Limited METHODS OF DETECTION OF TRANSTHYRETINE
AU2018345806A1 (en) * 2017-10-06 2020-03-12 Novo Nordisk A/S Anti-transthyretin antibodies
PH12020550694A1 (en) 2017-11-29 2021-04-12 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin
WO2020247452A1 (en) * 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
TW202525341A (zh) 2023-12-15 2025-07-01 丹麥商諾佛 儂迪克股份有限公司 穩定的液體調配物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100489892C (zh) 1999-02-05 2009-05-20 三星电子株式会社 恢复描述图像的纹理特征的图像纹理描述符的方法及装置
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
AU2003302689B2 (en) 2002-11-29 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Also Published As

Publication number Publication date
CO2017008469A2 (es) 2018-01-16
MX2017009804A (es) 2018-08-15
CA2974911A1 (en) 2016-08-04
BR112017016324A2 (pt) 2018-03-27
AU2016210887B2 (en) 2021-11-04
WO2016120809A1 (en) 2016-08-04
EP3250594A1 (en) 2017-12-06
JP6875280B2 (ja) 2021-05-26
SA517381991B1 (ar) 2021-12-13
MY193674A (en) 2022-10-24
US20160257736A1 (en) 2016-09-08
EP3250594B1 (en) 2021-11-17
PE20180200A1 (es) 2018-01-31
SG11201706125QA (en) 2017-08-30
TWI718121B (zh) 2021-02-11
TWI781507B (zh) 2022-10-21
TW202118782A (zh) 2021-05-16
JP7219928B2 (ja) 2023-02-09
JP2018509889A (ja) 2018-04-12
CU20170096A7 (es) 2018-03-13
KR20170120607A (ko) 2017-10-31
AU2016210887A1 (en) 2017-08-10
EA201791711A1 (ru) 2017-11-30
EA036048B1 (ru) 2020-09-18
ZA201705662B (en) 2018-08-29
KR102619359B1 (ko) 2024-01-02
CN107428822A (zh) 2017-12-01
TW201636372A (zh) 2016-10-16
MX391789B (es) 2025-03-21
JP2021129562A (ja) 2021-09-09
ES2905311T3 (es) 2022-04-07
CU24532B1 (es) 2021-07-02

Similar Documents

Publication Publication Date Title
CN107406500B (zh) 抗甲状腺素运载蛋白抗体
CN107406499B (zh) 抗甲状腺素运载蛋白抗体
CN107428822B (zh) 抗甲状腺素运载蛋白抗体
CN111315213B (zh) 抗甲状腺素运载蛋白抗体
AU2018345807B2 (en) Methods of detecting transthyretin
JP2019530427A (ja) 抗トランスサイレチン抗体
JP2019530428A (ja) 抗トランスサイレチン抗体
JP2019532617A (ja) 抗トランスサイレチン抗体
HK1240247B (en) Anti‐transthyretin antibodies
HK1240247A1 (en) Anti‐transthyretin antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240125

Address after: Baggswald, Denmark

Patentee after: NOVO NORDISK A/S

Country or region after: Denmark

Patentee after: University HEALTH NETWORK

Country or region after: Canada

Address before: Ai Erlandubailin

Patentee before: Neoto Neuroscience Ltd.

Country or region before: Ireland

Patentee before: University HEALTH NETWORK

Country or region before: Canada

Effective date of registration: 20240125

Address after: Ai Erlandubailin

Patentee after: Neoto Neuroscience Ltd.

Country or region after: Ireland

Patentee after: University HEALTH NETWORK

Country or region after: Canada

Address before: Ai Erlan,dubailin

Patentee before: PROTHENA BIOSCIENCES Ltd.

Country or region before: Ireland

Patentee before: University HEALTH NETWORK

Country or region before: Canada